Elicio is tackling this challenge with next-generation immunotherapies based on its proprietary Amphiphile (AMP) technology, which can effectively ferry immunomodulatory payloads—from small ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, ...

About the Amphiphile Platform Elicio’s proprietary AMP platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes.